<Disease><Name>GLYCOGEN STORAGE DISEASE TYPE II. ADULT ONSET</Name><Synonym>GSD2; GLYCOGEN STORAGE DISEASE II</Synonym><OMIM><Number>232300</Number><URL>http://omim.org/entry/232300</URL></OMIM><Orphanet><Number>420429</Number><URL>http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=420429</URL></Orphanet><Protein><Number>Lysosomal alpha-glucosidase</Number><URL>http://www.uniprot.org/uniprot/P10253</URL></Protein><ExPASy><Number>3.2.1.3</Number><URL>http://enzyme.expasy.org/EC/3.2.1.3</URL></ExPASy><Gene>17q25.3</Gene><ICD>E74.0</ICD><Summary>rare (1:100000 );autosomal recessive ;mutation in the GAA gene;1) infantile onset: cardiomegaly, progressive weakness, macroglossia;2) juvenile onset: (cardiac involvement), slower progression 3) adult onset: slowly progressive myopathy</Summary><Symptoms><symtomp><id>3178</id><symptom>dyspnea</symptom><category>LUNG OR RESPIRATORY SYSTEM</category></symtomp><symtomp><id>1716</id><symptom>fatigue, severe or unusual</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1925</id><symptom>headache (severe, recurrent or occipital, migraine)</symptom><category>GENERAL TOPICS | HEAD</category></symtomp><symtomp><id>1915</id><symptom>onset, adulthood / adoulthood</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>1890</id><symptom>progressive muscle defect</symptom><category>MUSCLES</category></symtomp><symtomp><id>2143</id><symptom>respiratory insufficiency / respiratory failure</symptom><category>LUNG OR RESPIRATORY SYSTEM</category></symtomp></Symptoms><Metabolites><metabolite><id>963</id><name>alpha-Glucosidase</name><specimen>fibroblasts</specimen><value>decreased</value><min>    </min><max>100.00</max><unit>% activity</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>964</id><name>alpha-Glucosidase</name><specimen>muscle</specimen><value>decreased</value><min>    </min><max>100.00</max><unit>% activity</unit><age>no data</age><method /><comment /></metabolite></Metabolites><Literatures><literature><id>7393</id><title>Novel Mutations Found in Individuals with Adult-Onset Pompe Disease</title><author>Aung-Htut MT,</author><journal>Genes (Basel)</journal><year>2020</year><book /><volume>11</volume><number>2</number><pages>E135</pages><co_aut>et al.</co_aut></literature><literature><id>7957</id><title>Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures</title><author>Vanherpe P,</author><journal>Orphanet J Rare Dis</journal><year>2020</year><book /><volume>15</volume><number>1</number><pages>83</pages><co_aut>et al.</co_aut></literature><literature><id>6956</id><title>Study of the effect of anti-rhGAA antibodies at low and intermediate titers in late onset Pompe patients treated with ERT</title><author>Fernandez-Simon E,</author><journal>Mol Genet Metab</journal><year>2019</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>6957</id><title>Assessing the Role of Anti rh-GAA in Modulating Response to ERT in a Late-Onset Pompe Disease Cohort from the Italian GSDII Stu</title><author>Filosto M,</author><journal>Adv Ther</journal><year>2019</year><book /><volume>36</volume><number>5</number><pages>1177-1189</pages><co_aut>et al.</co_aut></literature><literature><id>6958</id><title>Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study</title><author>Figueroa-Bonaparte S,</author><journal>Sci Rep</journal><year>2018</year><book /><volume>8</volume><number>1</number><pages>10898</pages><co_aut>et al.</co_aut></literature><literature><id>4029</id><title>New mutations and genotype-phenotype correlation in late-onset Pompe patients</title><author>Bekircan-Kurt CE,</author><journal>Acta Neurol Belg</journal><year>2017</year><book /><volume>117</volume><number>1</number><pages>269-275</pages><co_aut>et al.</co_aut></literature><literature><id>4030</id><title>The emerging phenotype of late-onset Pompe disease: A systematic literature review</title><author>Chan J,</author><journal>Mol Genet Metab</journal><year>2017</year><book /><volume>120</volume><number>3</number><pages>163-172</pages><co_aut>et al.</co_aut></literature><literature><id>4031</id><title>Practical Recommendations for Diagnosis and Management of Respiratory Muscle Weakness in Late-Onset Pompe Disease</title><author>Boentert M,</author><journal>Int J Mol Sci</journal><year>2016</year><book /><volume>17</volume><number>10</number><pages>e1735</pages><co_aut>et al.</co_aut></literature><literature><id>4032</id><title>Guidelines for the diagnosis, treatment and clinical monitoring of patients with juvenile and adult Pompe disease</title><author>Llerena Junior JC,</author><journal>Arq Neuropsiquiatr</journal><year>2016</year><book /><volume>74</volume><number>2</number><pages>166-176</pages><co_aut>et al.</co_aut></literature><literature><id>4033</id><title>Pompe disease: literature review and case series</title><author>Dasouki M,</author><journal>Neurol Clin</journal><year>2014</year><book /><volume>32</volume><number>3</number><pages>751-776</pages><co_aut>et al.</co_aut></literature><literature><id>144</id><title>Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency</title><author>Hirschhorn R</author><journal>The metabolic and molecular bases of inherited disease, 7/e; Editors: C.R.Scriver, A.L.Beaudet, W.S.Sly, D.Valle; McGraw-Hill Inc.</journal><year>1995</year><book /><volume>2</volume><number>0</number><pages>2443-2464</pages><co_aut /></literature></Literatures></Disease>